Clinical Trial Detail

NCT ID NCT03719326
Title A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer and Gynecologic Malignancies
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Arcus Biosciences, Inc.
Indications

triple-receptor negative breast cancer

ovarian cancer

Therapies

AB928 + IPI-549 + Pegylated liposomal-doxorubicin

AB928 + Pegylated liposomal-doxorubicin

Age Groups: adult senior

No variant requirements are available.